Sociedad Americana de Hirudoterapia

Botswana Medicines Regulatory Authority

BoMRA · Botswana · africa

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Botswana Medicines Regulatory Authority — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national pharmaceutical and medical device framework as appropriate.

Regulatory Profile

Agency type
national regulator
Region
africa
Country
Botswana
Leech status
unregulated
Last ASH review
2026-05-27

Relevant Regulation Codes

  • Botswana Medicines and Related Substances Act, 2013
  • Botswana national medical device regulatory framework
  • Southern African Development Community (SADC) harmonised pharmaceutical frameworks where applicable
  • African Medicines Agency (AMA) harmonised frameworks (where applicable)

Prescriber Requirements

  • Botswana Health Professions Council–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

BoMRA registration as applicable; English-language labelling. Standard cold-chain conditions, with logistical constraints typical of landlocked Southern African distribution.

Import/Export Rules

BoMRA and Department of Veterinary Services clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Botswana's public health system coverage depends on inpatient bundling; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. Southern African regulatory frameworks are progressively coordinating through SADC and the African Medicines Agency (AMA); whether this captures live-organism medical devices has not been independently mapped by ASH.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.